1446 related articles for article (PubMed ID: 8166929)
41. Effects of the bidentate malonate ligand on the utilization and cytotoxicity of platinum compounds in the L1210 cell line.
Mauldin SK; Husain I; Sancar A; Chaney SG
Cancer Res; 1986 Jun; 46(6):2876-82. PubMed ID: 3698013
[TBL] [Abstract][Full Text] [Related]
42. Chiral platinum(II) metallointercalators with potent in vitro cytotoxic activity.
Fisher DM; Bednarski PJ; Grünert R; Turner P; Fenton RR; Aldrich-Wright JR
ChemMedChem; 2007 Apr; 2(4):488-95. PubMed ID: 17340669
[TBL] [Abstract][Full Text] [Related]
43. Platinum (II) complexes with stereochemically-defined thiepane dioxide diamine ligands as anticancer drugs.
Cerè V; Grossi L; Munari D; Pollicino S; Martelli L; Martelli M
Anticancer Res; 2006; 26(3A):1815-9. PubMed ID: 16827112
[TBL] [Abstract][Full Text] [Related]
44. Asymmetrically substituted ethylenediamine platinum(II) complexes as antitumor agents: synthesis and structure-activity relationships.
Mailliet P; Segal-Bendirdjian E; Kozelka J; Barreau M; Baudoin B; Bissery MC; Gontier S; Laoui A; Lavelle F; Le Pecq JB
Anticancer Drug Des; 1995 Jan; 10(1):51-73. PubMed ID: 7695813
[TBL] [Abstract][Full Text] [Related]
45. Cisplatinum and transplatinum complexes with benzyliminoether ligands; synthesis, characterization, structure-activity relationships, and in vitro and in vivo antitumor efficacy.
Sbovata SM; Bettio F; Mozzon M; Bertani R; Venzo A; Benetollo F; Michelin RA; Gandin V; Marzano C
J Med Chem; 2007 Sep; 50(19):4775-84. PubMed ID: 17713897
[TBL] [Abstract][Full Text] [Related]
46. Growth, flow cytometric, and karyological characterization of L1210 cell sublines resistant to various Pt derivatives.
Hrubisko M; Kysela B; Kuliffay P
Neoplasma; 1989; 36(4):401-10. PubMed ID: 2770927
[TBL] [Abstract][Full Text] [Related]
47. Ammine/amine platinum (II) complexes effective in vivo against murine tumors sensitive or resistant to cisplatin and tetraplatin.
Siddik ZH; Thai G; Yoshida M; Zhang YP; Khokhar AR
J Cancer Res Clin Oncol; 1994; 120(10):571-7. PubMed ID: 7929527
[TBL] [Abstract][Full Text] [Related]
48. [The prospect for cisplatin analogs from the experimental standpoint].
Tashiro T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1358-65. PubMed ID: 2543305
[TBL] [Abstract][Full Text] [Related]
49. Activation of the trans geometry in platinum antitumor complexes: a survey of the cytotoxicity of trans complexes containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action.
Farrell N; Kelland LR; Roberts JD; Van Beusichem M
Cancer Res; 1992 Sep; 52(18):5065-72. PubMed ID: 1516063
[TBL] [Abstract][Full Text] [Related]
50. [Antitumor activity of a new platinum complex, (R)-(-)-2-aminomethylpyrrolidine (1, 1-cyclobutanedicarboxylato) platinum (II), against cisdiamminedichloroplatinum (II)-resistant murine leukemia cell line].
Akamatsu K; Endo K; Matsumoto T; Kamisango K; Morikawa K; Koizumi M; Mitsui H; Koizumi K; Matsuno T
Gan To Kagaku Ryoho; 1990 Jan; 17(1):73-8. PubMed ID: 2404458
[TBL] [Abstract][Full Text] [Related]
51. Synthesis, in vitro cytotoxic and antiviral activity of cis-[Pt(R(-) and S(+)-2-alpha-hydroxybenzylbenzimidazole)2Cl2] complexes.
Gökçe M; Utku S; Gür S; Ozkul A; Gümüş F
Eur J Med Chem; 2005 Feb; 40(2):135-41. PubMed ID: 15694648
[TBL] [Abstract][Full Text] [Related]
52. Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes.
Kelland LR; Barnard CF; Evans IG; Murrer BA; Theobald BR; Wyer SB; Goddard PM; Jones M; Valenti M; Bryant A
J Med Chem; 1995 Aug; 38(16):3016-24. PubMed ID: 7636864
[TBL] [Abstract][Full Text] [Related]
53. New isomeric azine-bridged dinuclear platinum(II) complexes circumvent cross-resistance to cisplatin.
Komeda S; Kalayda GV; Lutz M; Spek AL; Yamanaka Y; Sato T; Chikuma M; Reedijk J
J Med Chem; 2003 Mar; 46(7):1210-9. PubMed ID: 12646031
[TBL] [Abstract][Full Text] [Related]
54. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
55. Role of DNA replication in carrier-ligand-specific resistance to platinum compounds in L1210 cells.
Gibbons GR; Kaufmann WK; Chaney SG
Carcinogenesis; 1991 Dec; 12(12):2253-7. PubMed ID: 1747924
[TBL] [Abstract][Full Text] [Related]
56. Comparative antitumor studies on platinum(II) and platinum(IV) complexes containing 1,2-diaminocyclohexane.
Vollano JF; Al-Baker S; Dabrowiak JC; Schurig JE
J Med Chem; 1987 Apr; 30(4):716-9. PubMed ID: 3560163
[TBL] [Abstract][Full Text] [Related]
57. Toxicity and anti-tumor activity of hydrophobic diammine and diaminocyclohexane platinum complexes entrapped in multilamellar vesicles.
Khokhar AR; Al-Baker S; Perez-Soler R
Anticancer Drug Des; 1988 Dec; 3(3):177-84. PubMed ID: 3207465
[TBL] [Abstract][Full Text] [Related]
58. Treatment and prophylaxis of experimental liver metastases of M5076 reticulosarcoma with cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) encapsulated in multilamellar vesicles.
Perez-Soler R; Khokhar AR; Lopez-Berestein G
Cancer Res; 1987 Dec; 47(24 Pt 1):6462-6. PubMed ID: 3315188
[TBL] [Abstract][Full Text] [Related]
59. In vitro effect of Pt and Pd mercaptopyridine complexes.
Carrara M; Berti T; D'Ancona S; Cherchi V; Sindellari L
Anticancer Res; 1997; 17(2A):975-80. PubMed ID: 9137437
[TBL] [Abstract][Full Text] [Related]
60. Synthesis, characterization and antitumor activity of novel octahedral Pt(IV) complexes.
Kwon YE; Whang KJ; Park YJ; Kim KH
Bioorg Med Chem; 2003 Apr; 11(8):1669-76. PubMed ID: 12659753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
